1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)
Miles, D., Cameron, D., Bondarenko, I., Lyudmila, M., Alcedo, J.C., Lopez, R.I., Im, S.A., Canon, J.L., Shparyk, Y., Yardley, D., Masuda, N., Ro, J., Hubeaux, S., Quah, C., Bais, C., O'Shaughnessy, J.Volume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)30816-4
Date:
September, 2015
File:
PDF, 74 KB
english, 2015
File converter
More search results
More benefits 
